HC Wainwright Reaffirms “Buy” Rating for ImmunoPrecise Antibodies (NASDAQ:IPA)

ImmunoPrecise Antibodies (NASDAQ:IPA)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $7.00 price target on the stock.

ImmunoPrecise Antibodies Stock Down 5.0 %

NASDAQ IPA opened at $0.38 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.01 and a debt-to-equity ratio of 0.36. ImmunoPrecise Antibodies has a fifty-two week low of $0.27 and a fifty-two week high of $1.64. The business has a 50 day moving average price of $0.46 and a two-hundred day moving average price of $0.50. The stock has a market cap of $11.96 million, a PE ratio of -0.49 and a beta of 0.09.

Institutional Investors Weigh In On ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC lifted its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,558,892 shares of the company’s stock after acquiring an additional 263,451 shares during the quarter. Ingalls & Snyder LLC owned 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent filing with the SEC. Institutional investors own 6.70% of the company’s stock.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.